Acute bacterial rhinosinusitis: A review of U.S. treatment guidelines

Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 3, 2006, Pages 341-348

  Marple, Bradley F ^a   Brunton, Stephen ^b   Ferguson, Berrylin J ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFDINIR; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; IMMUNIZATION; INFECTION RISK; MEDICAL SOCIETY; MORAXELLA CATARRHALIS; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RHINOSINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PRACTICE GUIDELINES; RHINITIS; SINUSITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33747891058     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2005.12.021     Document Type: Review

References (54)

1. Sinus and Allergy Health Partnership (SAHP). Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 130 (2004) 1-45
2. Clayman G.L., Adams G.L., Paugh D.R., et al. Intracranial complications of paranasal sinusitis: a combined institutional review. Laryngoscope 101 (1991) 234-239
3. Hytönen M., Atula T., and Pitkäranta A. Complications of acute sinusitis in children. Acta Otolaryngol Suppl 543 (2000) 154-157
4. Wu J.H., Howard D.H., McGowan Jr. J.E., et al. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia. Clin Ther 26 (2004) 2153-2162
5. Snow V., Mottur-Pilson C., Hickner J.M., American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine, Centers for Disease Control, and Infectious Diseases Society of America. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med 134 (2001) 495-497
6. The Institute for Clinical Systems Improvement (ICSI). Acute sinusitis in adults. Available at www.icsi.org/knowledge/detail.asp?catID=29&itemID=148. (accessed May 11, 2005).
7. Williams Jr. J.W., and Simel D.L. Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination. JAMA 270 (1993) 1242-1246
8. Gwaltney Jr. J.M., Phillips C.D., Miller R.D., et al. Computed tomographic study of the common cold. N Engl J Med 330 (1994) 25-30
9. Hickner J.M., Bartlett J.G., Besser R.E., et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med 134 (2001) 498-505
10. Berg O., Carenfelt C., and Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis 20 (1988) 511-516
11. Gwaltney Jr. J.M., Scheld W.M., Sande M.A., et al. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 90 3 Pt 2 (1992) 457-461
12. Brook I. Microbiology and management of sinusitis. J Otolaryngol 25 (1996) 249-256
13. Felmingham D., Feldman C., Hryniewicz W., et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 8 suppl 2 (2002) 12-42
14. Sahm D.F., Jones M.E., Hickey M.L., et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 45 (2000) 457-466
15. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am J Med 111 suppl 9A (2001) 19S-24S
16. Jacobs M.R., Felmingham D., Appelbaum P.C., et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52 (2003) 229-246
17. Dohar J., Canton R., Cohen R., et al. Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis. Ann Clin Microbiol Antimicrob 3 (2004) 15
18. Farrell D.J., Rybak M.J., and Patel M. Prevalence of β-lactamase production among Haemophilus influenzae isolates collected in the US over a three-year period (2000-2003) and the in vitro activity of telithromycin (2004) [Abstract C2-807]. In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC, USA
19. Jenkins S.G., Farrell D.J., Patel M., et al. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect (2005) [Epub ahead of print]
20. Mera R.M., Miller L.A., Daniels J.J., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 51 (2005) 195-200
21. Brown S.D., and Rybak M.J. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 54 suppl 1 (2004) i7-i15
22. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286 (2001) 1857-1862
23. Granizo J.J., Aguilar L., Casal J., et al. Streptococcus pneumoniaeresistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 46 (2000) 767-773
24. Dias R., and Caniça M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14. J Antimicrob Chemother 54 (2004) 1035-1039
25. Vanderkooi O.G., Low D.E., Green K., et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 40 (2005) 1288-1297
26. Jacobs M.R. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med 106 (1999) 19S-25S
27. Pelton S.I., Loughlin A.M., and Marchant C.D. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23 (2004) 1015-1022
28. Farrell D.J., Klugman K., and Pichichero M.E. Increase in antibacterial resistance of nonvaccine serotypes of Streptococcus pneumoniae in the US following introduction of the PCV7 vaccine (2005) [Abstract TBD]. In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, Washington, DC, USA
29. Huang S.S., Platt R., Rifas-Shiman S.L., et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 (2005) e408-e413
30. Brown E.M., and Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 55 (2005) 6-9
31. Masterton R.G. Antibiotic cycling: more than it might seem?. J Antimicrob Chemother 55 (2005) 1-5
32. Agency for Health Care Policy and Research (AHCPR). Diagnosis and treatment of acute bacterial rhinosinusitis. Available at: http://www.ahrq.gov/clinic/epcsums/sinussum.htm. (accessed May 11, 2005).
33. Kiani R., Johnson D., and Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med 85 (1988) 6-13
34. White A.R., Kaye C., Poupard J., et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 53 suppl 1 (2004) i3-i20
35. Calvo A., Amores R., Valero E., et al. Activity of oral antibiotics against respiratory tract pathogens in Spain. Rev Esp Quimioter 16 (2003) 436-443
36. Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 21 (1999) 3-40
37. Ferrara A.M. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 33 (2005) 106-114
38. Bishai W. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. Clin Ther 24 (2002) 838-850
39. Pankuch G.A., Visalli M.A., Jacobs M.R., et al. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 42 (1998) 624-630
40. Biedenbach D.J., Barrett M.S., and Jones R.N. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 31 (1998) 349-353
41. Iannini P., Stager W., Sharma K., et al. Results from a 24,000 patient mega-trial comparing telithromycin (TEL) and amoxicillin/clavulanate (AM) in the treatment of community-acquired respiratory tract infections (2002) [Abstract L-24]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Late-Breaker Program/Abstracts Addendum, September 27-30, San Diego, CA, USA
42. Stratton C.W. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 9 (2003) 10-16
43. Zhanel G.G., Dueck M., Hoban D.J., et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61 (2001) 443-498
44. Klossek J.M., and Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 59 (2005) 230-238
45. Neuhauser M.M., Weinstein R.A., Rydman R., et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289 (2003) 885-888
46. Bhavnani S.M., and Andes D.R. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 25 (2005) 717-740
47. Saravolatz L., Manzor O., Pawlak J., et al. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int J Antimicrob Agents 26 (2005) 81-84
48. Kuehnel T.S., Schurr C., Lotter K., et al. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chemother 55 (2005) 591-594
49. Buchanan P.P., Stephens T.A., and Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 17 (2003) 369-377
50. Luterman M., Tellier G., Lasko B., et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 82 (2003) 576-586
51. Ferguson B.J., Guzzetta R.V., Spector S.L., et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 131 (2004) 207-214
52. Roos K., Tellier G., Baz M., et al. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect 50 (2005) 210-220
53. Marple B.F. Dilemma in trial design: do current study designs adequately evaluate antibiotic effectiveness in ABRS?. Otolaryngol Head Neck Surg 133 (2005) 200-201
54. Poole M.D. A mathematical therapeutic outcomes model for sinusitis. Otolaryngol Head Neck Surg 130 1 suppl (2004) 46-50